Rather than stimulating immune cells to more effectively battle cancerous tumors, treatment with the protein interleukin-12 (IL-12) has the opposite effect, driving these intracellular fighters to exhaustion, a Mayo Clinic study has found. The findings appear in the Journal of Clinical Investigation. The study helps explain the negative results of ...

(Rutgers University) Rutgers researchers have uncovered a new way to stimulate activity of immune cell opiate receptors, leading to efficient tumor cell clearance. The researchers have been able to take a new pharmacological approach to activate the immune cells to prevent cancer growth through stimulation of the opiate receptors found ...

Untangling the root cause of rheumatoid arthritis has been a difficult task for immunologists, as decades of research has pointed to multiple culprits in our immune system, with contradictory lines of evidence. Now, researchers at The Wistar Institute announce that it takes a diverse array of regulatory T cells (a ...

(Scripps Research Institute) Scientists at the Scripps Research Institute have found the first chemical compounds that act to block an enzyme that has been linked to inflammatory conditions such as asthma and arthritis, as well as some inflammation-promoted cancers.

ROCHESTER, Minn. -- Rather than stimulating immune cells to more effectively battle cancerous tumors, treatment with the protein interleukin-12 (IL-12) has the opposite effect, driving these intracellular fighters to exhaustion, a Mayo Clinic study has found. The findings appear in the Journal of Clinical Investigation . The ...

(Mayo Clinic) Rather than stimulating immune cells to more effectively battle cancerous tumors, treatment with the protein interleukin-12 has the opposite effect, driving these intracellular fighters to exhaustion, a Mayo Clinic study has found.

Untangling the root cause of rheumatoid arthritis has been a difficult task for immunologists, as decades of research has pointed to multiple culprits in our immune system, with contradictory lines of evidence. Now, researchers at The Wistar Institute announce that it takes a diverse array of regulatory T cells (a ...

(The Wistar Institute) To stop rheumatoid arthritis, it takes the collective efforts of a diverse array of regulatory T cells and not just a T cell primed to handle the disease-causing self-antigen, according to Wistar researchers.

A new study helps to resolve an ongoing controversy about whether Langerhans cells (LCs) in human skin function to suppress the immune response and promote tolerance to normal human skin and its "friendly" microbial flora or mobilize a lethal attack against harmful foreign invaders. The research, published online in the ...

(American Society of Hematology) A new analysis concludes that rituximab, a drug commonly used to treat blood cancers, leads to treatment responses lasting at least five years in approximately one quarter of patients with low platelet counts and a risk of bleeding due to chronic immune thrombocytopenic purpura. In study ...

A new analysis may help doctors identify breast cancer patients who will benefit from treatment with the immune suppressant drug everolimus, say French researchers at the 4th IMPAKT Breast Cancer Conference in Brussels, Belgium. Everolimus is currently used as an immunosuppressant to prevent patients rejecting transplanted organs and in the ...

A pioneering approach to imaging breast cancer in mice has revealed new clues about why the human immune system often fails to attack tumors and keep cancer in check. This observation, by scientists at the University of California, San Francisco (UCSF), may help to reveal new approaches to cancer immunotherapy. ...